Antibiotic susceptibility patterns at the Médecins Sans Frontières (MSF) Acute Trauma Hospital in Aden, Yemen: a retrospective study from January 2018 to June 2021.

BACKGROUND: Antimicrobial resistance (AMR) is an urgent global health concern, especially in countries facing instability or conflicts, with compromised healthcare systems. Médecins Sans Frontières (MSF) established an acute trauma hospital in Aden, Yemen, treating mainly war-wounded civilians, and implemented an antimicrobial stewardship (AMS) programme. This study aimed to describe clinical characteristics and identify antibiotic susceptibility patterns representative of patients treated with antibiotics.

METHODS: Retrospective cross-sectional study using routinely collected data from all patients treated with antibiotics in the MSF-Aden Acute Trauma hospital between January 2018 and June 2021. Routine clinical data from patients' files was entered into an AMS electronic database and microbiological data were entered into WHONET. Both databases were imported and merged in REDCap and analysed using RStudio.

RESULTS: Three hundred and sixty-three of 481 (75%) included patients were injured by violence-related trauma. Most were men aged 19-45 years ( = 331; 68.8%). In total, 598 infections were diagnosed and treated. MDR organisms were identified in 362 (60.5%) infections in 311 (65%) patients. Skin and soft-tissue infections (SSTIs) ( = 143; 24%) were the most common, followed by osteomyelitis ( = 125; 21%) and intra-abdominal-infections (IAIs) ( = 116; 19%), and 111 (19%) secondary bloodstream infections were identified. was the most frequently identified pathogen, causing IAI ( = 87; 28%) and SSTI ( = 43; 16%), while caused mainly osteomyelitis ( = 84; 19%). Most Gram-negatives were ESBL producers, including ( = 193; 81.4%), ( = 72; 77.4%) and ( = 39; 50%) while most were methicillin resistant ( = 93; 72.6%).

CONCLUSIONS: High rates of MDR were found. This information will facilitate a comprehensive review of the empirical antibiotic treatment guidelines.

© The Author(s) 2024. Published by Oxford University Press on behalf of British Society for Antimicrobial Chemotherapy.